These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 26087191)

  • 1. COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization.
    Wu YH; Chang TH; Huang YF; Chen CC; Chou CY
    Oncotarget; 2015 Sep; 6(27):23748-63. PubMed ID: 26087191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression.
    Wu YH; Huang YF; Chen CC; Chou CY
    Cell Death Dis; 2019 Apr; 10(4):322. PubMed ID: 30975980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer.
    Wu YH; Chang TH; Huang YF; Huang HD; Chou CY
    Oncogene; 2014 Jun; 33(26):3432-40. PubMed ID: 23934190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-κB-mediated IKKβ expression.
    Wu YH; Huang YF; Chang TH; Chou CY
    Int J Cancer; 2017 Dec; 141(11):2305-2317. PubMed ID: 28815582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes.
    Teng PN; Wang G; Hood BL; Conrads KA; Hamilton CA; Maxwell GL; Darcy KM; Conrads TP
    Br J Cancer; 2014 Jan; 110(1):123-32. PubMed ID: 24178762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
    Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
    Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-335 Restrains the Aggressive Phenotypes of Ovarian Cancer Cells by Inhibiting COL11A1.
    Wu YH; Huang YF; Chang TH; Wu PY; Hsieh TY; Hsiao SY; Huang SC; Chou CY
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The downregulation of miR-509-3p expression by collagen type XI alpha 1-regulated hypermethylation facilitates cancer progression and chemoresistance via the DNA methyltransferase 1/Small ubiquitin-like modifier-3 axis in ovarian cancer cells.
    Wu YH; Huang YF; Wu PY; Chang TH; Huang SC; Chou CY
    J Ovarian Res; 2023 Jun; 16(1):124. PubMed ID: 37386587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer.
    Lee S; Choi S; Lee Y; Chung D; Hong S; Park N
    J Obstet Gynaecol Res; 2017 Jan; 43(1):220-227. PubMed ID: 27862665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
    Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
    BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
    Fraser M; Bai T; Tsang BK
    Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein.
    Abedini MR; Muller EJ; Bergeron R; Gray DA; Tsang BK
    Oncogene; 2010 Jan; 29(1):11-25. PubMed ID: 19802016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
    Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
    Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells.
    Yang H; He L; Kruk P; Nicosia SV; Cheng JQ
    Int J Cancer; 2006 Nov; 119(10):2304-12. PubMed ID: 16894566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rab25 is responsible for phosphoinositide 3-kinase/AKT‑mediated cisplatin resistance in human epithelial ovarian cancer cells.
    Fan Y; Wang L; Han X; Liu X; Ma H
    Mol Med Rep; 2015 Mar; 11(3):2173-8. PubMed ID: 25405658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer.
    Rada M; Nallanthighal S; Cha J; Ryan K; Sage J; Eldred C; Ullo M; Orsulic S; Cheon DJ
    Oncogene; 2018 Aug; 37(35):4809-4820. PubMed ID: 29769618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.
    Guo P; Xiong X; Zhang S; Peng D
    Oncol Rep; 2016 Dec; 36(6):3552-3558. PubMed ID: 27748936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation.
    Liu D; Zhang XX; Li MC; Cao CH; Wan DY; Xi BX; Tan JH; Wang J; Yang ZY; Feng XX; Ye F; Chen G; Wu P; Xi L; Wang H; Zhou JF; Feng ZH; Ma D; Gao QL
    Nat Commun; 2018 Apr; 9(1):1739. PubMed ID: 29712898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.